MARKET

REGN

REGN

Regeneron Pharms
NASDAQ

Real-time Quotes | Nasdaq Last Sale

638.90
-7.61
-1.18%
After Hours: 639.71 +0.81 +0.13% 17:51 09/24 EDT
OPEN
644.31
PREV CLOSE
646.51
HIGH
644.31
LOW
632.45
VOLUME
654.47K
TURNOVER
--
52 WEEK HIGH
686.62
52 WEEK LOW
441.00
MARKET CAP
68.33B
P/E (TTM)
11.47
1D
5D
1M
3M
1Y
5Y
WHO Backs Regeneron COVID-19 Antibody Cocktail As It Calls For Equal Access
Benzinga · 1d ago
Dare (DARE) Begins Study to Treat Vulvar and Vaginal Atrophy
Zacks.com · 1d ago
CDC head overrules advisers to allow COVID-19 boosters be offered to at-risk workers, and Biden urges eligible to act fast
In an unusual move, the head of the Centers for Disease Control and Prevention overruled a panel of advisers' recommendation that booster doses of a COVID-19 vaccine be offered only to people over 65 and those with weakened immune systems, allowing them to...
Marketwatch.com · 1d ago
BELLUS (BLU) Completes Enrollment in Two Mid-Stage Studies
Zacks.com · 1d ago
10 Best Healthcare Stocks to Buy According to Matthew Halbower’s Pentwater Capital Management
In this article, we discuss the 10 best healthcare stocks to buy according to Matthew Halbower’s Pentwater Capital Management. If you want to skip our detailed analysis of Halbower’s history, investment philosophy, and hedge fund performance, go directly t...
Insider Monkey · 1d ago
U.S. Household Net Worth Hits Record High in Q2: 5 Picks
We have narrowed down our search to five large-cap stocks that have given double-digit returns in the past three months. These are: CLR, DAR, REGN, ORLY and MOS.
Zacks · 1d ago
WHO recommends Regeneron's monoclonal antibody treatment for COVID-19
Shares of Regeneron Pharmaceuticals Inc. were down 0.1% in premarket trading on Friday after the World Health Organization recommended its monoclonal antibody as a treatment for COVID-19. The global body says the combination treatment can be used in COVID-...
MarketWatch · 1d ago
WHO backs Regeneron COVID-19 drug cocktail as UN body calls for equal access
WHO backs Regeneron COVID-19 drug cocktail as UN body calls for equal access
reuters.com · 1d ago
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of REGN. Analyze the recent business situations of Regeneron Pharms through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 26 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average REGN stock price target is 686.88 with a high estimate of 831.00 and a low estimate of 545.00.
EPS
Institutional Holdings
Institutions: 1.28K
Institutional Holdings: 93.04M
% Owned: 86.99%
Shares Outstanding: 106.96M
TypeInstitutionsShares
Increased
356
4.29M
New
148
1.19M
Decreased
292
5.65M
Sold Out
88
327.99K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-2.13%
Pharmaceuticals & Medical Research
-1.02%
Key Executives
Chairman/Director
P. Roy Vagelos
President/Chief Executive Officer/Founder/Director
Leonard Schleifer
Co-President/Chief Scientific Officer/Director
George Yancopoulos
Chief Financial Officer/Executive Vice President - Finance
Robert Landry
Executive Vice President/General Counsel/Secretary
Joseph LaRosa
Executive Vice President/General Manager
Daniel Van Plew
Executive Vice President
Marion McCourt
Executive Vice President
Andrew Murphy
Executive Vice President
Neil Stahl
Senior Vice President/Controller
Christopher Fenimore
Independent Director
Bonnie Bassler
Independent Director
Michael Brown
Independent Director
N. Anthony Coles
Independent Director
Joseph Goldstein
Independent Director
Christine Poon
Independent Director
Arthur Ryan
Independent Director
George Sing
Independent Director
Marc Tessier-Lavigne
Independent Director
Huda Zoghbi
No Data
  • All
  • Financials
  • Insiders
More
About REGN
Regeneron Pharmaceuticals, Inc. is a biotechnology company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious diseases. The Company commercializes medicines and product candidates for eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, pain, infectious diseases, and rare diseases. The Company's marketed products include EYLEA (aflibercept) Injection, Dupixent (dupilumab) Injection, Libtayo (cemiplimab) Injection, Praluent (alirocumab) Injection, Kevzara (sarilumab) Solution for Subcutaneous Injection, Inmazeb (atoltivimab, maftivimab, and odesivimab-ebgn) Injection, ARCALYST (rilonacept) Injection for Subcutaneous Use and ZALTRAP (ziv-aflibercept) Injection for Intravenous Infusion.

Webull offers kinds of Regeneron Pharmaceuticals Inc stock information, including NASDAQ:REGN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, REGN stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading REGN stock methods without spending real money on the virtual paper trading platform.